Zenas BioPharma, Inc.
ZBIO
$34.50
-$2.57-6.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.00M | 15.00M | 15.00M | 5.00M | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.00M | 15.00M | 15.00M | 5.00M | 0.00 |
| Cost of Revenue | 161.50M | 160.63M | 151.41M | 139.14M | 110.40M |
| Gross Profit | -146.50M | -145.63M | -136.41M | -134.14M | -110.40M |
| SG&A Expenses | 49.20M | 43.47M | 37.23M | 29.75M | 22.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 210.70M | 204.10M | 188.64M | 168.89M | 133.04M |
| Operating Income | -195.70M | -189.10M | -173.64M | -163.89M | -133.04M |
| Income Before Tax | -189.66M | -176.76M | -162.54M | -156.56M | -128.67M |
| Income Tax Expenses | 244.00K | 244.00K | 224.00K | 429.00K | 301.00K |
| Earnings from Continuing Operations | -189.90 | -177.01 | -162.76 | -156.99 | -128.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -189.90M | -177.01M | -162.76M | -156.99M | -128.97M |
| EBIT | -195.70M | -189.10M | -173.64M | -163.89M | -133.04M |
| EBITDA | -195.62M | -189.00M | -173.51M | -163.75M | -132.91M |
| EPS Basic | -4.53 | -8.32 | -31.30 | -48.39 | -63.08 |
| Normalized Basic EPS | -2.75 | -5.20 | -19.56 | -30.24 | -39.18 |
| EPS Diluted | -4.53 | -8.32 | -31.30 | -48.39 | -63.08 |
| Normalized Diluted EPS | -2.75 | -5.20 | -19.56 | -30.24 | -39.18 |
| Average Basic Shares Outstanding | 167.76M | 133.30M | 93.00M | 52.75M | 12.36M |
| Average Diluted Shares Outstanding | 167.76M | 133.30M | 93.00M | 52.75M | 12.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |